{"transactions":[{"id":671288,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":1452,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023."}],"balance_after":60858,"derivative":{"exercise_price":1.86,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":1452},"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":671287,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":1452,"price":25.47,"value":36982.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":671286,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-09-01T21:19:15.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":1452,"price":1.86,"value":2700.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":118679,"source":{"system":"sec-edgar","filing":"0001817160-26-000019","document":"wk-form4_1788297552.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000019/wk-form4_1788297552.xml","form_type":"4"}},{"id":695816,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":false,"shares":4356,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 1/48 of the total shares monthly beginning June 10, 2019 until the option was fully vested on May 10, 2023."}],"balance_after":62310,"derivative":{"exercise_price":1.86,"expiration_date":"2029-08-28","underlying":"Common Stock","underlying_shares":4356},"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695815,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"sale","planned":true,"acquired":false,"shares":4356,"price":25,"value":108900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695814,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T22:59:04.000Z","date":"2026-08-05","kind":"exercise","planned":true,"acquired":true,"shares":4356,"price":1.86,"value":8102.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":121583,"source":{"system":"sec-edgar","filing":"0001817160-26-000017","document":"wk-form4_1785970741.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000017/wk-form4_1785970741.xml","form_type":"4"}},{"id":695813,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T10:39:37.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":2611,"price":24.6415,"value":64338.9565,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $24.43 and the highest price at which shares were sold was $24.83. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":117227,"source":{"system":"sec-edgar","filing":"0001817160-26-000015","document":"wk-form4_1785926375.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000015/wk-form4_1785926375.xml","form_type":"4"}},{"id":695812,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-08-05T10:39:37.000Z","date":"2026-08-04","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":23.8684,"value":35802.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.42 and the highest price at which shares were sold was $24.38. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":119838,"source":{"system":"sec-edgar","filing":"0001817160-26-000015","document":"wk-form4_1785926375.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000015/wk-form4_1785926375.xml","form_type":"4"}},{"id":700743,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":39303,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3572},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700742,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20009,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700741,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":11250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700740,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"sale","planned":false,"acquired":false,"shares":3847,"price":23.3828,"value":89953.6316,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.00 and the highest price at which shares were sold was $23.90. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":121338,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700739,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3572,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125185,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700738,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":121613,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":700737,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-07-30T21:50:22.000Z","date":"2026-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":118755,"source":{"system":"sec-edgar","filing":"0001817160-26-000012","document":"wk-form4_1785448219.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000012/wk-form4_1785448219.xml","form_type":"4"}},{"id":726505,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-06-25T22:49:10.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":5394,"price":20,"value":107880.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person."}],"balance_after":115005,"source":{"system":"sec-edgar","filing":"0001817160-26-000010","document":"wk-form4_1782427748.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000010/wk-form4_1782427748.xml","form_type":"4"}},{"id":796958,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22867,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796957,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":15000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796956,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796955,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"sale","planned":false,"acquired":false,"shares":3214,"price":16.6453,"value":53497.9942,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.51 and the highest price at which shares were sold was $16.78. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":120399,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796954,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":123613,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796953,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":120755,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":796952,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-04-30T21:35:55.000Z","date":"2026-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":117005,"source":{"system":"sec-edgar","filing":"0001817160-26-000008","document":"wk-form4_1777584953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000008/wk-form4_1777584953.xml","form_type":"4"}},{"id":912170,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-02-10T22:50:25.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":42875,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2026, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":42875,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":42875},"source":{"system":"sec-edgar","filing":"0001817160-26-000006","document":"wk-form4_1770763822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000006/wk-form4_1770763822.xml","form_type":"4"}},{"id":912169,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-10T22:50:25.000Z","date":"2026-02-10","kind":"grant","planned":false,"acquired":true,"shares":93750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 10, 2026, until the option is fully vested on February 9, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":93750,"derivative":{"exercise_price":16.45,"expiration_date":"2036-02-09","underlying":"Common Stock","underlying_shares":93750},"source":{"system":"sec-edgar","filing":"0001817160-26-000006","document":"wk-form4_1770763822.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000006/wk-form4_1770763822.xml","form_type":"4"}},{"id":922102,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2026-02-04T02:12:37.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":false,"shares":31333,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":0.84,"expiration_date":"2026-02-10","underlying":"Common Stock","underlying_shares":31333},"source":{"system":"sec-edgar","filing":"0001817160-26-000004","document":"wk-form4_1770171154.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000004/wk-form4_1770171154.xml","form_type":"4"}},{"id":922101,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-02-04T02:12:37.000Z","date":"2026-02-03","kind":"exercise","planned":false,"acquired":true,"shares":31333,"price":0.84,"value":26319.72,"ownership":{"direct":true},"balance_after":115005,"source":{"system":"sec-edgar","filing":"0001817160-26-000004","document":"wk-form4_1770171154.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000004/wk-form4_1770171154.xml","form_type":"4"}},{"id":927086,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":false,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":25725,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2859},"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927085,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":18750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927084,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":2000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927083,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927082,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"sale","planned":false,"acquired":false,"shares":98,"price":17.3717,"value":1702.4266,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $17.33 and the highest price at which shares were sold was $17.49. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":83672,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927081,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"sale","planned":false,"acquired":false,"shares":4797,"price":16.5826,"value":79546.7322,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $16.33 and the highest price at which shares were sold was $17.32. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":83770,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927080,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":true,"shares":2859,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":88567,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927079,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":85708,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927078,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":81958,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":927077,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2026-01-31T01:36:55.000Z","date":"2026-01-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":79958,"source":{"system":"sec-edgar","filing":"0001817160-26-000002","document":"wk-form4_1769823412.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716026000002/wk-form4_1769823412.xml","form_type":"4"}},{"id":1011415,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":28584,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011414,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011413,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":4000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011412,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":3207,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011411,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"sale","planned":false,"acquired":false,"shares":4087,"price":12.7967,"value":52300.1129,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $12.68 and the highest price at which shares were sold was $12.89. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":76751,"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011410,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":80838,"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011409,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":77980,"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011408,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":74230,"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1011407,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-10-30T22:01:02.000Z","date":"2025-10-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":72230,"source":{"system":"sec-edgar","filing":"0001817160-25-000005","document":"wk-form4_1761861659.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000005/wk-form4_1761861659.xml","form_type":"4"}},{"id":1014244,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-10-23T23:04:57.000Z","date":"2025-10-14","kind":"grant","planned":false,"acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs will vest on the second anniversary of the date of grant, subject to the Reporting Person's continuous services to the Issuer from the date of grant through such vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001817160-25-000003","document":"wk-form4_1761260695.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000181716025000003/wk-form4_1761260695.xml","form_type":"4"}},{"id":1079222,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":31442,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2858},"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079221,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":26250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079220,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":6000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079219,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":6414,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079218,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"sale","planned":false,"acquired":false,"shares":4308,"price":12.011,"value":51743.388,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $11.78 and the highest price at which shares were sold was $12.315. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":69023,"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079217,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2858,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":73331,"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079216,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":70473,"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079215,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":66723,"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1079214,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-07-30T22:48:55.000Z","date":"2025-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64723,"source":{"system":"sec-edgar","filing":"0001549595-25-000099","document":"wk-form4_1753915731.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000099/wk-form4_1753915731.xml","form_type":"4"}},{"id":1163416,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":30000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163415,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":8000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163414,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":9621,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3206},"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163413,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"sale","planned":false,"acquired":false,"shares":3377,"price":11.5017,"value":38841.2409,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $11.05 and the highest price at which shares were sold was $11.72. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":61516,"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163412,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":64893,"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163411,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":61143,"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1163410,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-30T23:35:40.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3206,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":59143,"source":{"system":"sec-edgar","filing":"0001549595-25-000061","document":"wk-form4_1746056133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000061/wk-form4_1746056133.xml","form_type":"4"}},{"id":1269737,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-02-13T21:11:58.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":34300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":34300,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":34300},"source":{"system":"sec-edgar","filing":"0001549595-25-000032","document":"wk-form4_1739481109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000032/wk-form4_1739481109.xml","form_type":"4"}},{"id":1269736,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2025-02-13T21:11:58.000Z","date":"2025-02-11","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 11, 2025, until the option is fully vested on February 10, 2028, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":17.12,"expiration_date":"2035-02-10","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001549595-25-000032","document":"wk-form4_1739481109.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000032/wk-form4_1739481109.xml","form_type":"4"}},{"id":1290855,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":33750,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290854,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":10000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290853,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":12827,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290852,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"sale","planned":false,"acquired":false,"shares":333,"price":20.3256,"value":6768.4248,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $20.28 and the highest price at which shares were sold was $20.39. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":55937,"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290851,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"sale","planned":false,"acquired":false,"shares":3357,"price":19.8068,"value":66491.4276,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $19.28 and the highest price at which shares were sold was $20.275. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":56270,"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290850,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":59627,"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290849,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55877,"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1290848,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-31T00:48:14.000Z","date":"2025-01-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":53877,"source":{"system":"sec-edgar","filing":"0001549595-25-000022","document":"wk-form4_1738284487.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959525000022/wk-form4_1738284487.xml","form_type":"4"}},{"id":1379431,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":37500,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379430,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":12000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379429,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":16034,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379428,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"sale","planned":false,"acquired":false,"shares":3437,"price":24.305,"value":83536.285,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $23.98 and the highest price at which shares were sold was $24.77. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":50670,"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379427,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":54107,"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379426,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":50357,"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1379425,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-10-31T00:30:17.000Z","date":"2024-10-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48357,"source":{"system":"sec-edgar","filing":"0001549595-24-000147","document":"wk-form4_1730334611.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000147/wk-form4_1730334611.xml","form_type":"4"}},{"id":1446361,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":41250,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3750},"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446360,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":14000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446359,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock upon settlement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":19241,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446358,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"sale","planned":false,"acquired":false,"shares":3408,"price":20.6677,"value":70435.5216,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $20.48 and the highest price at which shares were sold was $20.96. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":45150,"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446357,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3750,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48558,"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446356,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":44808,"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1446355,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-07-30T23:06:21.000Z","date":"2024-07-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":42808,"source":{"system":"sec-edgar","filing":"0001549595-24-000106","document":"wk-form4_1722380775.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000106/wk-form4_1722380775.xml","form_type":"4"}},{"id":1532909,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-30T22:33:20.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":16000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-24-000054","document":"wk-form4_1714516389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000054/wk-form4_1714516389.xml","form_type":"4"}},{"id":1532908,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-04-30T22:33:20.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":false,"shares":3206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":22448,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3206},"source":{"system":"sec-edgar","filing":"0001549595-24-000054","document":"wk-form4_1714516389.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000054/wk-form4_1714516389.xml","form_type":"4"}},{"id":1532907,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-30T22:33:20.000Z","date":"2024-04-30","kind":"sale","planned":false,"acquired":false,"shares":2007,"price":12.0422,"value":24168.6954,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $11.9050 and the highest price at which shares were sold was $12.2000. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":39601,"source":{"system":"sec-edgar","filing":"0001549595-24-000054","document":"wk-form4_1714516389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000054/wk-form4_1714516389.xml","form_type":"4"}},{"id":1532906,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-30T22:33:20.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":41608,"source":{"system":"sec-edgar","filing":"0001549595-24-000054","document":"wk-form4_1714516389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000054/wk-form4_1714516389.xml","form_type":"4"}},{"id":1532905,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-04-30T22:33:20.000Z","date":"2024-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3206,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":39608,"source":{"system":"sec-edgar","filing":"0001549595-24-000054","document":"wk-form4_1714516389.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000054/wk-form4_1714516389.xml","form_type":"4"}},{"id":1641153,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-02-15T12:23:04.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":45000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001549595-24-000018","document":"wk-form4_1707999774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000018/wk-form4_1707999774.xml","form_type":"4"}},{"id":1641152,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-02-15T12:23:04.000Z","date":"2024-02-13","kind":"grant","planned":false,"acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests as to 1/36 of the total shares monthly beginning March 13, 2024, until the option is fully vested on February 13, 2027, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":150000,"derivative":{"exercise_price":8.72,"expiration_date":"2034-02-12","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001549595-24-000018","document":"wk-form4_1707999774.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000018/wk-form4_1707999774.xml","form_type":"4"}},{"id":1666680,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-30T23:52:58.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":18000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-24-000008","document":"wk-form4_1706658767.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000008/wk-form4_1706658767.xml","form_type":"4"}},{"id":1666679,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2024-01-30T23:52:58.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":false,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":25654,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":3207},"source":{"system":"sec-edgar","filing":"0001549595-24-000008","document":"wk-form4_1706658767.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000008/wk-form4_1706658767.xml","form_type":"4"}},{"id":1666678,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-30T23:52:58.000Z","date":"2024-01-30","kind":"sale","planned":false,"acquired":false,"shares":2334,"price":7.9902,"value":18649.1268,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units (\"RSUs\"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents the weighted average sale price. The lowest price at which shares were sold was $7.93 and the highest price at which shares were sold was $8.06. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein."}],"balance_after":36402,"source":{"system":"sec-edgar","filing":"0001549595-24-000008","document":"wk-form4_1706658767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000008/wk-form4_1706658767.xml","form_type":"4"}},{"id":1666677,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-30T23:52:58.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":38736,"source":{"system":"sec-edgar","filing":"0001549595-24-000008","document":"wk-form4_1706658767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000008/wk-form4_1706658767.xml","form_type":"4"}},{"id":1666676,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-30T23:52:58.000Z","date":"2024-01-30","kind":"exercise","planned":false,"acquired":true,"shares":3207,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":36736,"source":{"system":"sec-edgar","filing":"0001549595-24-000008","document":"wk-form4_1706658767.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959524000008/wk-form4_1706658767.xml","form_type":"4"}},{"id":1752516,"issuer":{"id":1156,"kind":"organization","name":"Nurix Therapeutics, Inc.","symbol":"NRIX"},"owners":[{"id":17989,"kind":"person","name":"Hansen Gwenn","position":1,"cik":"0001817160","reported_name":"Hansen Gwenn","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Restricted Stock Units","published_at":"2023-11-01T20:40:40.000Z","date":"2023-10-30","kind":"exercise","planned":false,"acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"RSUs do not expire; they either vest or are canceled prior to the vest date."}],"balance_after":20000,"derivative":{"exercise_price":0,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001549595-23-000058","document":"wk-form4_1698871229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1817160/000154959523000058/wk-form4_1698871229.xml","form_type":"4"}}],"next_cursor":"2023-11-01T20:40:40.000000Z,1752516"}